Related references
Note: Only part of the references are listed.Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China
Zhiliang Hu et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)
Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies
Maryam Noori et al.
REVIEWS IN MEDICAL VIROLOGY (2022)
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
Shengli Xia et al.
LANCET INFECTIOUS DISEASES (2021)
An Observational Laboratory-Based Assessment of SARS-CoV-2 Molecular Diagnostics in Benin, Western Africa
Anna-Lena Sander et al.
MSPHERE (2021)
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
Patrick Tang et al.
NATURE MEDICINE (2021)
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
Koen B. Pouwels et al.
NATURE MEDICINE (2021)
Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
Barak Mizrahi et al.
NATURE COMMUNICATIONS (2021)
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
Chris Davis et al.
PLOS PATHOGENS (2021)
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight US Locations, December 2020-March 2021
Mark G. Thompson et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
Ian McDonald et al.
NPJ VACCINES (2021)
Assessing COVID-19 Vaccine Hesitancy, Confidence, and Public Engagement: A Global Social Listening Study
Zhiyuan Hou et al.
JOURNAL OF MEDICAL INTERNET RESEARCH (2021)
Considerations in boosting COVID-19 vaccine immune responses
Philip R. Krause et al.
LANCET (2021)
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
Aziz Sheikh et al.
LANCET (2021)
COVID VACCINE BOOSTERS: THE MOST IMPORTANT QUESTIONS
Ewen Callaway
NATURE (2021)
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
Hiam Chemaitelly et al.
NATURE MEDICINE (2021)
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
Alejandro Jara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Lifting of COVID-19 restrictions in the UK and the Delta variant
Talha Khan Burki
LANCET RESPIRATORY MEDICINE (2021)
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021
Srinivas Nanduri et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021
Ashley Fowlkes et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021
Shaun J. Grannis et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Dealing with vaccine hesitancy in Africa: the prospective COVID-19 vaccine context
Aanuoluwapo Adeyimika Afolabi et al.
PAN AFRICAN MEDICAL JOURNAL (2021)
Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study
Xiao-Ning Li et al.
EMERGING MICROBES & INFECTIONS (2021)
Emergency Use Authorization of Remdesivir The Need for a Transparent Distribution Process
Michael G. Ison et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Pedro M. Folegatti et al.
LANCET (2020)
The epidemiological burden of and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: evidence from a systematic review and meta-analysis
Rashidul Alam Mahumud et al.
INFECTION (2020)
Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Federica Fogacci et al.
DRUGS (2019)
Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data
Zachary Munn et al.
INTERNATIONAL JOURNAL OF EVIDENCE-BASED HEALTHCARE (2015)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis
JAC Sterne et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2001)